Lansoprazol Teva

Lansoprazole, the active ingredient in Lansoprazol Teva, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid production and is employed in the management of acid‑related disorders such as gastro‑oesophageal reflux disease, peptic ulcer disease, and for ulcer prevention in patients taking non‑steroidal anti‑inflammatory drugs. The medication is formulated for systemic absorption and is indicated for both treatment and maintenance therapy in these conditions.

GNH USA supplies Lansoprazol Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazole is indicated for several acid‑related conditions that involve excessive gastric secretion.

- Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and esophageal irritation by maintaining a higher gastric pH. - Peptic ulcer disease: promotes ulcer healing by suppressing acid that impedes mucosal repair. - NSAID‑induced ulcer prophylaxis: reduces the risk of ulcer formation in patients receiving chronic non‑steroidal anti‑inflammatory therapy. - Helicobacter pylori eradication (as part of combination therapy): enhances bacterial clearance by creating a less acidic gastric environment.

Lansoprazole may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Diarrhea: loose stools that may resolve with continued therapy. - Nausea: occasional feeling of queasiness, usually mild. - Abdominal pain: discomfort in the upper abdomen. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reactions (e.g., angioedema, anaphylaxis): require immediate medical attention. - Clostridioides difficile infection: presents with watery diarrhea and abdominal cramping. - Elevated liver enzymes: may indicate hepatic stress. - Hypomagnesemia: low serum magnesium with prolonged use. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: rare skin reactions. - Interstitial nephritis: inflammation of kidney tissue.

When prescribing Lansoprazole, clinicians should consider several precautionary measures to ensure safe use.

- Renal impairment: assess kidney function before initiating therapy. - Hepatic impairment: use with caution in patients with liver disease. - Long‑term use: monitor for vitamin B12 deficiency and bone density loss. - Known hypersensitivity: avoid in individuals with documented allergy to lansoprazole or other PPIs. - Pregnancy and lactation: prescribe only if the potential benefit justifies the potential risk. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lansoprazole can alter the plasma concentrations of other medicines; awareness of key interactions helps avoid therapeutic failures or toxicity.

Major Interactions (Avoid): - Clarithromycin: may increase lansoprazole levels, raising the risk of adverse effects. - Ketoconazole: reduced absorption of ketoconazole due to higher gastric pH. - Atazanavir: decreased atazanavir exposure, compromising antiviral efficacy.

Moderate Interactions (Monitor Closely): - Rifampin: induces metabolism of lansoprazole, potentially lowering its effectiveness. - Warfarin: may enhance anticoagulant effect; monitor INR closely.